國立虎尾科技大學 |

Lung cancer and personalized medicine = current knowledge and therapies /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Lung cancer and personalized medicine/ edited by Aamir Ahmad, Shirish Gadgeel.
Reminder of title:	current knowledge and therapies /
other author:	Ahmad, Aamir.
Published:	Cham :Springer International Publishing : : 2016.,
Description:	xiii, 228 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Lungs - Cancer -
Online resource:	http://dx.doi.org/10.1007/978-3-319-24223-1
ISBN:	9783319242231

Lung cancer and personalized medicine = current knowledge and therapies /
Lung cancer and personalized medicinecurrent knowledge and therapies /[electronic resource] :edited by Aamir Ahmad, Shirish Gadgeel. - Cham :Springer International Publishing :2016. - xiii, 228 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.8930065-2598 ;. - Advances in experimental medicine and biology ;780..

1 Lung Cancer Statistics -- 2 Epidemiology of Lung Cancer -- 3 Lung Cancer In Never Smokers -- 4 Immune Therapy -- 5 Anti-angiogenesis in personalized therapy of lung cancer -- 6 Target therapy in Lung Cancer -- 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: an update -- 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy -- 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer -- 10 Chemotherapy Resistance in Lung Cancer -- 11 Current state of metal-based drugs for the efficient therapy of lung cancers and lung metastases.

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer--statistics and epidemiology of lung cancer--along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer--immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.

ISBN: 9783319242231

Standard No.: 10.1007/978-3-319-24223-1doiSubjects--Topical Terms:

798534
Lungs
--Cancer

LC Class. No.: RC280.L8

Dewey Class. No.: 616.9942406

Lung cancer and personalized medicine = current knowledge and therapies /
LDR:02535nam a2200325 a 4500 001 861341
003 DE-He213
005 20160802153656.0
006 m d
007 cr nn 008maaau
008 170720s2016 gw s 0 eng d
020 $a 9783319242231 $q (electronic bk.)
020 $a 9783319242217 $q (paper)
024 7 $a 10.1007/978-3-319-24223-1 $2 doi
035 $a 978-3-319-24223-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.9942406 $2 23
090 $a RC280.L8 $b L963 2016
245 0 0 $a Lung cancer and personalized medicine $h [electronic resource] : $b current knowledge and therapies / $c edited by Aamir Ahmad, Shirish Gadgeel.
260 $a Cham : $c 2016. $b Springer International Publishing : $b Imprint: Springer,
300 $a xiii, 228 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.893
505 0 $a 1 Lung Cancer Statistics -- 2 Epidemiology of Lung Cancer -- 3 Lung Cancer In Never Smokers -- 4 Immune Therapy -- 5 Anti-angiogenesis in personalized therapy of lung cancer -- 6 Target therapy in Lung Cancer -- 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: an update -- 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy -- 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer -- 10 Chemotherapy Resistance in Lung Cancer -- 11 Current state of metal-based drugs for the efficient therapy of lung cancers and lung metastases.
520 $a This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer--statistics and epidemiology of lung cancer--along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer--immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.
650 0 $a Lungs $x Cancer $x Treatment. $3 798534
650 0 $a Personalized medicine. $3 1027491
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
650 2 4 $a Internal Medicine. $3 668583
650 2 4 $a Oncology. $3 593951
700 1 $a Ahmad, Aamir. $3 1072728
700 1 $a Gadgeel, Shirish. $3 1103674
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 780. $3 881230
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-24223-1
950 $a Biomedical and Life Sciences (Springer-11642)